K. Nozaki

发表

The Effect of Granisetron on In Vitro Metabolism of Paclitaxel and Docetaxel

Yoh Watanabe, H. Nakajima, K. Nozaki, 2003, Cancer journal.

Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy

I. Narita, K. Nakata, Daisuke Ishikawa, 2015, The Journal of Immunology.

Carboplatin hypersensitivity induced by low‐dose paclitaxel/carboplatin in multiple platinum‐treated patients with recurrent ovarian cancer

K. Nozaki, H. Hoshiai, H. Ueda, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer

K. Nozaki, H. Hoshiai, H. Ueda, 2004, International Journal of Gynecologic Cancer.

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC

Daisuke Ishikawa, Hiroshi Tanaka, Kosuke Ichikawa, 2022, Scientific reports.

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report

K. Nishio, T. Kikuchi, Satoshi Watanabe, 2021, Translational cancer research.

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Kazuhiro Sato, Hiroshi Tanaka, Aya Ohtsubo, 2021, Frontiers in Oncology.

Prognostic significance of procalcitonin in small cell lung cancer

Aya Ohtsubo, Kosuke Ichikawa, T. Kikuchi, 2021, Translational lung cancer research.

PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer

Miyuki Sato, Aya Ohtsubo, Kosuke Ichikawa, 2021, Cancer Immunology, Immunotherapy.

Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells

Miyuki Sato, Aya Ohtsubo, Kosuke Ichikawa, 2017, PloS one.

immunity during recovery from lymphopenia Depletion of radio-resistant regulatory T cells enhances antitumor

I. Narita, K. Nakata, Hiroshi Tanaka, 2013 .

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases

Kazuhiro Sato, T. Ishida, Hiroshi Tanaka, 2019, Thoracic cancer.

Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy

I. Narita, K. Nakata, Daisuke Ishikawa, 2015, The Journal of Immunology.

after Lymphodepleting Chemotherapy Regulatory T Cells in Antitumor Immunity Critical Roles of Chemoresistant Effector and

K. Nakata, Daisuke Ishikawa, Kosuke Ichikawa, 2015 .

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease

Kazuhiro Sato, Hiroshi Tanaka, Aya Ohtsubo, 2021, Translational lung cancer research.

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy

Kazuhiro Sato, T. Ishida, Hiroshi Tanaka, 2020, Cancer medicine.

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC

Daisuke Ishikawa, Hiroshi Tanaka, Kosuke Ichikawa, 2021, Scientific reports.

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

K. Nishio, Daisuke Ishikawa, T. Sekiya, 2022, Cancers.

Clinicopathologic and Immunohistochemical Features and Microsatellite Status of Endometrial Cancer of the Uterine Isthmus

K. Nozaki, Yoh Watanabe, H. Nakajima, 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations

Y. Ajioka, Hiroshi Tanaka, Miyuki Sato, 2019, PloS one.

Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity

Miyuki Sato, Aya Ohtsubo, Kosuke Ichikawa, 2021, Scientific Reports.

DDX3X mediates EGFR-TKI resistance through VEGFR signaling

Takaaki Masuda, T. Sekiya, Aya Ohtsubo, 2021 .

DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations

I. Narita, Aya Ohtsubo, H. Kagamu, 2014, PloS one.

Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.

I. Narita, K. Nakata, Hiroshi Tanaka, 2012, Blood.

Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors

I. Narita, Daisuke Ishikawa, Aya Ohtsubo, 2016, BMC Cancer.